Age
Item
age ≥18
boolean
C0001779 (UMLS CUI [1])
Adenocarcinoma of prostate
Item
histologically confirmed adenocarcinoma of the prostate.
boolean
C0007112 (UMLS CUI [1])
Orchiectomy
Item
orchidectomy within the four previous weeks to enter the study.
boolean
C0029189 (UMLS CUI [1])
Secondary malignant neoplasm of bone Scan of bone
Item
bone metastasis evidenced by bone scan.
boolean
C0153690 (UMLS CUI [1,1])
C0203668 (UMLS CUI [1,2])
Hip DEXA scan
Item
a hip dexa study with a ds < 3.
boolean
C1272029 (UMLS CUI [1])
Hormone Therapy
Item
no hormonal therapy previous to enter the study.
boolean
C0279025 (UMLS CUI [1])
ECOG performance status
Item
ecog performance score of 0-2.
boolean
C1520224 (UMLS CUI [1])
Informed Consent
Item
signed written informed consent.
boolean
C0021430 (UMLS CUI [1])
Abnormal renal function | Creatinine clearance measurement
Item
abnormal renal function evidenced by a creatinine clearance ≤60 ml/min.
boolean
C0151746 (UMLS CUI [1])
C0373595 (UMLS CUI [2])
Hormone Therapy Prostate carcinoma
Item
any kind of hormonal therapy for prostate cancer previous to enter the study.
boolean
C0279025 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
Corrected serum calcium measurement | Serum albumin measurement
Item
serum calcium corrected for albumin level < 8.0 mg/dl.
boolean
C0455288 (UMLS CUI [1])
C0523465 (UMLS CUI [2])
White Blood Cell Count procedure | Absolute neutrophil count | Hemoglobin | Platelet Count measurement
Item
wbc < 3.0x10^3, anc < 1500/mm3, hemoglobin < 8.0 g/dl, platelets < 75 x 10^3/l.
boolean
C0023508 (UMLS CUI [1])
C0948762 (UMLS CUI [2])
C0019046 (UMLS CUI [3])
C0032181 (UMLS CUI [4])
Liver Dysfunction | Alanine aminotransferase measurement | Aspartate aminotransferase measurement
Item
abnormal hepatic function evidenced by alt and ast value >2.5 unl
boolean
C0086565 (UMLS CUI [1])
C0201836 (UMLS CUI [2])
C0201899 (UMLS CUI [3])
Malignant Neoplasm Affecting Bone
Item
subjects with any other malignant disease that can affect the bone.
boolean
C0006826 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0262950 (UMLS CUI [1,3])
Disease Non-Malignant At risk Clinical Trial | Osteoporosis Severe | Disease Non-Malignant Preventing Trial Evaluation
Item
subjects with any other non malignant disease that can jeopardize the evaluation of the primary objectives of this trial (severe osteoporosis) or that do not aloud perform the trial evaluations.
boolean
C0012634 (UMLS CUI [1,1])
C1518371 (UMLS CUI [1,2])
C1444641 (UMLS CUI [1,3])
C0008976 (UMLS CUI [1,4])
C0029456 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0012634 (UMLS CUI [3,1])
C1518371 (UMLS CUI [3,2])
C1292733 (UMLS CUI [3,3])
C0008976 (UMLS CUI [3,4])
C0220825 (UMLS CUI [3,5])
Hypersensitivity zoledronic acid | Hypersensitivity Diphosphonates
Item
known hypersensibility to zoledronic acid or other bisphosphonates.
boolean
C0020517 (UMLS CUI [1,1])
C0257685 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0012544 (UMLS CUI [2,2])
Protocol Compliance Unable
Item
subjects that in the investigator's opinion can not cooperate with the protocol.
boolean
C0525058 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
Clinical Trial Eligibility Criteria Additional
Item
other protocol inclusion/exclusion criteria may apply.
boolean
C1516637 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])